Chemistry (all); Biochemistry, Genetics and Molecular Biology (all); Physics and Astronomy (all); General Physics and Astronomy; General Biochemistry, Genetics and Molecular Biology; General Chemistry
Résumé :
[en] Despite the high prevalence of both cervico-vaginal human papillomavirus (HPV) infection and bacterial vaginosis (BV) worldwide, their causal relationship remains unclear. While BV has been presumed to be a risk factor for HPV acquisition and related carcinogenesis for a long time, here, supported by both a large retrospective follow-up study (n = 6,085) and extensive in vivo data using the K14-HPV16 transgenic mouse model, we report a novel blueprint in which the opposite association also exists. Mechanistically, by interacting with several core members (NEMO, CK1 and β-TrCP) of both NF-κB and Wnt/β-catenin signaling pathways, we show that HPV E7 oncoprotein greatly inhibits host defense peptide expression. Physiologically secreted by the squamous mucosa lining the lower female genital tract, we demonstrate that some of these latter are fundamental factors governing host-microbial interactions. More specifically, several innate molecules down-regulated in case of HPV infection are hydrolyzed, internalized and used by the predominant Lactobacillus species as amino acid source sustaining their growth/survival. Collectively, this study reveals a new viral immune evasion strategy which, by its persistent/negative impact on lactic acid bacteria, ultimately causes the dysbiosis of vaginal microbiota.
Disciplines :
Microbiologie
Auteur, co-auteur :
Lebeau, Alizée ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Biologie cellulaire et moléculaire
Bruyère, Diane ✱; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
RONCARATI, Patrick ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques
Peixoto, Paul ; INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, France ; EPIGENEXP platform, University of Bourgogne Franche-Comté, Besançon, France
Hervouet, Eric ; INSERM, EFS BFC, UMR 1098, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, University of Bourgogne Franche-Comté, Besançon, France ; EPIGENEXP platform, University of Bourgogne Franche-Comté, Besançon, France
COBRAIVILLE, Gaël ; Centre Hospitalier Universitaire de Liège - CHU > > Service de rhumatologie
Taminiau, Bernard ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire
Masson, Murielle ; Ecole Supérieure de Biotechnologie Strasbourg, UMR 7242, CNRS, University of Strasbourg, Illkirch, France
Gallego, Carmen; INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, University of Paris-Saclay, Clamart, France
Hendrick, Elodie ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Pilard, Charlotte ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Lerho, Thomas ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Reynders, Célia ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Ancion, Marie ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
GREIMERS, Roland ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques
Twizere, Jean-Claude ; Université de Liège - ULiège > Département GxABT > Microbial, food and biobased technologies
Daube, Georges ; Université de Liège - ULiège > Fundamental and Applied Research for Animals and Health (FARAH) > FARAH: Santé publique vétérinaire
Schlecht-Louf, Geraldine ; INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, University of Paris-Saclay, Clamart, France
Bachelerie, Françoise; INSERM UMR 996, Inflammation Microbiome and Immunosurveillance, University of Paris-Saclay, Clamart, France
Combes, Jean-Damien; Infections and Cancer Epidemiology Group, International Agency for Research on Cancer, World Health Organization, Lyon, France
MELIN, Pierrette ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques
Fillet, Marianne ; Université de Liège - ULiège > Unités de recherche interfacultaires > Centre Interdisciplinaire de Recherche sur le Médicament (CIRM)
DELVENNE, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'anatomie et cytologie pathologiques
Hubert, Pascale ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
Herfs, Michael ; Université de Liège - ULiège > GIGA > GIGA Cancer - Experimental Pathology
We thank the Biobank of the University of Liege, the Laboratory of Clinical Microbiology as well as the GIGA-Immunohistochemistry, in vitro imaging, genomics and viral vectors facilities (University of Liege) for their assistance. We are also grateful to Dr Stephanie Gofflot, Dr Wouter Coppieters, Dr Emmanuel Di Valentin, Manon Deckers, Latifa Karim, Cecile Meex, Raphael Thonon, Kamilia El Kandoussi, and Nancy Rosiere for their technical assistance. We sincerely thank Prof Bernard Joris and Dr Ana Amoroso (Laboratory of Bacterial Physiology and Genetics, University of Liege), Prof Christine Jacobs-Wagner (Microbial Sciences Institute, Yale University) as well as Dr Olivier Peulen (Metastasis Research Laboratory, University of Liege) for helpful discussions. This work was supported in part by the University of Liege [Crédits Sectoriels de Recherche en Sciences de la Santé 2018-2020 (M.H.)], the Belgian Fund for Scientific Research [FNRS; MIS F.4520.20, CDR J.0088.21 (M.H.)], the Televie [PDR Televie 7.8507.19 (M.H.)], the Léon Frédéricq Foundation and the Seventh Framework Program for Research and Technological Development [European Commission: Infect-ERA 2015 (HPV-Motiva)]. C.P., T.L., C.R., and M.A. are Televie/FRIA fellows. A.L., D.B., and EloH are postdoctoral researchers. MH is a Research Associate at the FNRS.We thank the Biobank of the University of Liege, the Laboratory of Clinical Microbiology as well as the GIGA-Immunohistochemistry, in vitro imaging, genomics and viral vectors facilities (University of Liege) for their assistance. We are also grateful to Dr Stephanie Gofflot, Dr Wouter Coppieters, Dr Emmanuel Di Valentin, Manon Deckers, Latifa Karim, Cecile Meex, Raphael Thonon, Kamilia El Kandoussi, and Nancy Rosiere for their technical assistance. We sincerely thank Prof Bernard Joris and Dr Ana Amoroso (Laboratory of Bacterial Physiology and Genetics, University of Liege), Prof Christine Jacobs-Wagner (Microbial Sciences Institute, Yale University) as well as Dr Olivier Peulen (Metastasis Research Laboratory, University of Liege) for helpful discussions. This work was supported in part by the University of Liege [Cr?dits Sectoriels de Recherche en Sciences de la Sant? 2018-2020 (M.H.)], the Belgian Fund for Scientific Research [FNRS; MIS F.4520.20, CDR J.0088.21 (M.H.)], the Televie [PDR Televie 7.8507.19 (M.H.)], the L?on Fr?d?ricq Foundation and the Seventh Framework Program for Research and Technological Development [European Commission: Infect-ERA 2015 (HPV-Motiva)]. C.P., T.L., C.R., and M.A. are Televie/FRIA fellows. A.L., D.B., and EloH are postdoctoral researchers. MH is a Research Associate at the FNRS.
de Sanjose, S. et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect. Dis. 7, 453–459 (2007).
de Martel, C., Plummer, M., Vignat, J. & Franceschi, S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. International journal of cancer. J. Int. du cancer 141, 664–670 (2017).
Schiffman, M. et al. Carcinogenic human papillomavirus infection. Nat. Rev. Dis. Prim. 2, 16086 (2016).
Luo, X. et al. HPV16 drives cancer immune escape via NLRX1-mediated degradation of STING. J. Clin. Investig. 130, 1635–1652 (2020).
Chang, Y. E. & Laimins, L. A. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74, 4174–4182 (2000).
Reiser, J. et al. High-risk human papillomaviruses repress constitutive kappa interferon transcription via E6 to prevent pathogen recognition receptor and antiviral-gene expression. J. Virol. 85, 11372–11380 (2011).
Ronco, L. V., Karpova, A. Y., Vidal, M. & Howley, P. M. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev. 12, 2061–2072 (1998).
Bottley, G. et al. High-risk human papillomavirus E7 expression reduces cell-surface MHC class I molecules and increases susceptibility to natural killer cells. Oncogene 27, 1794–1799 (2008).
Hasan, U. A. et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178, 3186–3197 (2007).
Karim, R. et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 6, e17848 (2011).
Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
Zhou, X. et al. Characterization of vaginal microbial communities in adult healthy women using cultivation-independent methods. Microbiology 150, 2565–2573 (2004).
Anahtar, M. N., Gootenberg, D. B., Mitchell, C. M. & Kwon, D. S. Cervicovaginal microbiota and reproductive health: the virtue of simplicity. Cell host microbe 23, 159–168 (2018).
Onderdonk, A. B., Delaney, M. L. & Fichorova, R. N. The human microbiome during bacterial vaginosis. Clin. Microbiol. Rev. 29, 223–238 (2016).
Turovskiy, Y., Sutyak Noll, K. & Chikindas, M. L. The aetiology of bacterial vaginosis. J. Appl. Microbiol. 110, 1105–1128 (2011).
Muzny, C. A. & Schwebke, J. R. Pathogenesis of bacterial vaginosis: discussion of current hypotheses. J. Infect. Dis. 214, S1–S5 (2016).
Leitich, H. et al. Bacterial vaginosis as a risk factor for preterm delivery: a meta-analysis. Am. J. Obstet. Gynecol. 189, 139–147 (2003).
Sweet, R. L. Gynecologic conditions and bacterial vaginosis: implications for the non-pregnant patient. Infect. Dis. Obstet. Gynecol. 8, 184–190 (2000).
Cherpes, T. L., Meyn, L. A., Krohn, M. A., Lurie, J. G. & Hillier, S. L. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 37, 319–325 (2003).
Cohen, C. R. et al. Bacterial vaginosis associated with increased risk of female-to-male HIV-1 transmission: a prospective cohort analysis among African couples. PLoS Med. 9, e1001251 (2012).
Wiesenfeld, H. C., Hillier, S. L., Krohn, M. A., Landers, D. V. & Sweet, R. L. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin. Infect. Dis.: Off. Publ. Infect. Dis. Soc. Am. 36, 663–668 (2003).
Brotman, R. M. et al. Interplay between the temporal dynamics of the vaginal microbiota and human papillomavirus detection. J. Infect. Dis. 210, 1723–1733 (2014).
Briselden, A. M., Moncla, B. J., Stevens, C. E. & Hillier, S. L. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J. Clin. Microbiol. 30, 663–666 (1992).
Mitra, A. et al. The vaginal microbiota associates with the regression of untreated cervical intraepithelial neoplasia 2 lesions. Nat. Commun. 11, 1999 (2020).
Brusselaers, N., Shrestha, S., van de Wijgert, J. & Verstraelen, H. Vaginal dysbiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am. J. Obstet. Gynecol. 221, 9–18 e18 (2019).
Gillet, E. et al. Bacterial vaginosis is associated with uterine cervical human papillomavirus infection: a meta-analysis. BMC Infect. Dis. 11, 10 (2011).
Kyrgiou, M., Mitra, A. & Moscicki, A. B. Does the vaginal microbiota play a role in the development of cervical cancer? Transl. Res.: J. Lab. Clin. Med. 179, 168–182 (2017).
Liang, Y., Chen, M., Qin, L., Wan, B. & Wang, H. A meta-analysis of the relationship between vaginal microecology, human papillomavirus infection and cervical intraepithelial neoplasia. Infect. agents cancer 14, 29 (2019).
Yarbrough, V. L., Winkle, S. & Herbst-Kralovetz, M. M. Antimicrobial peptides in the female reproductive tract: a critical component of the mucosal immune barrier with physiological and clinical implications. Hum. Reprod. Update 21, 353–377 (2015).
Wang, G., Li, X. & Wang, Z. APD3: the antimicrobial peptide database as a tool for research and education. Nucleic Acids Res. 44, D1087–D1093 (2016).
Tsutsumi-Ishii, Y. & Nagaoka, I. NF-kappa B-mediated transcriptional regulation of human beta-defensin-2 gene following lipopolysaccharide stimulation. J. Leukoc. Biol. 71, 154–162 (2002).
Johansen, C., Bertelsen, T., Ljungberg, C., Mose, M. & Iversen, L. Characterization of TNF-alpha- and IL-17A-mediated synergistic induction of DEFB4 gene expression in human keratinocytes through IkappaBzeta. J. Investig. Dermatol. 136, 1608–1616 (2016).
Clauss, A. et al. Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia 12, 161–172 (2010).
Dreos, R., Ambrosini, G., Perier, R. C. & Bucher, P. The Eukaryotic Promoter Database: expansion of EPDnew and new promoter analysis tools. Nucleic acids Res. 43, D92–D96 (2015).
Dang, C. V. et al. The c-Myc target gene network. Semin. cancer Biol. 16, 253–264 (2006).
Fernandez, P. C. et al. Genomic targets of the human c-Myc protein. Genes Dev. 17, 1115–1129 (2003).
He, T. C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512 (1998).
Jeanes, A., Gottardi, C. J. & Yap, A. S. Cadherins and cancer: how does cadherin dysfunction promote tumor progression? Oncogene 27, 6920–6929 (2008).
Schroeder, B. O. et al. Paneth cell alpha-defensin 6 (HD-6) is an antimicrobial peptide. Mucosal Immunol. 8, 661–671 (2015).
Schroeder, B. O. et al. Reduction of disulphide bonds unmasks potent antimicrobial activity of human beta-defensin 1. Nature 469, 419–423 (2011).
Torcia, M. G. Interplay among vaginal microbiome, immune response and sexually transmitted viral infections. Int. J. Mol. Sci. 20, (2019).
Lu, H. et al. Characteristics of bacterial vaginosis infection in cervical lesions with high risk human papillomavirus infection. Int J. Clin. Exp. Med. 8, 21080–21088 (2015).
Moscicki, A. B., Shi, B., Huang, H., Barnard, E. & Li, H. Cervical-vaginal microbiome and associated cytokine profiles in a prospective study of HPV 16 acquisition, persistence, and clearance. Front Cell Infect. Microbiol. 10, 569022 (2020).
Cheng, L. et al. Vaginal microbiota and human papillomavirus infection among young Swedish women. NPJ Biofilms Microbiomes 6, 39 (2020).
Lee, J. E. et al. Association of the vaginal microbiota with human papillomavirus infection in a Korean twin cohort. PLoS ONE 8, e63514 (2013).
Mitra, A. et al. Cervical intraepithelial neoplasia disease progression is associated with increased vaginal microbiome diversity. Sci. Rep. 5, 16865 (2015).
Perkins, R. B. et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors. J. Low. Genit. Trac. Dis. 24, 102–131 (2020).
DasGupta, T. et al. Human papillomavirus oncogenic E6 protein regulates human beta-defensin 3 (hBD3) expression via the tumor suppressor protein p53. Oncotarget 7, 27430–27444 (2016).
Nguyen, H., Teskey, L., Lin, R. & Hiscott, J. Identification of the secretory leukocyte protease inhibitor (SLPI) as a target of IRF-1 regulation. Oncogene 18, 5455–5463 (1999).
Um, S. J. et al. Abrogation of IRF-1 response by high-risk HPV E7 protein in vivo. Cancer Lett. 179, 205–212 (2002).
Hasan, U. A. et al. The human papillomavirus type 16 E7 oncoprotein induces a transcriptional repressor complex on the Toll-like receptor 9 promoter. J. Exp. Med. 210, 1369–1387 (2013).
Suarez-Carmona, M., Hubert, P., Delvenne, P. & Herfs, M. Defensins: “Simple” antimicrobial peptides or broad-spectrum molecules? Cytokine growth factor Rev. 26, 361–370 (2015).
Hancock, R. E., Haney, E. F. & Gill, E. E. The immunology of host defence peptides: beyond antimicrobial activity. Nat. Rev. Immunol. 16, 321–334 (2016).
Hubert, P. et al. Defensins induce the recruitment of dendritic cells in cervical human papillomavirus-associated (pre)neoplastic lesions formed in vitro and transplanted in vivo. FASEB J.: Off. Publ. Federation Am. Societies Exp. Biol. 21, 2765–2775 (2007).
Hubert, P. et al. Altered alpha-defensin 5 expression in cervical squamocolumnar junction: implication in the formation of a viral/tumour-permissive microenvironment. J. Pathol. 234, 464–477 (2014).
Wolf, R. et al. Chemotactic activity of S100A7 (Psoriasin) is mediated by the receptor for advanced glycation end products and potentiates inflammation with highly homologous but functionally distinct S100A15. J. Immunol. 181, 1499–1506 (2008).
Presicce, P., Giannelli, S., Taddeo, A., Villa, M. L. & Della Bella, S. Human defensins activate monocyte-derived dendritic cells, promote the production of proinflammatory cytokines, and up-regulate the surface expression of CD91. J. Leukoc. Biol. 86, 941–948 (2009).
Wiens, M. E. & Smith, J. G. Alpha-defensin HD5 inhibits furin cleavage of human papillomavirus 16 L2 to block infection. J. Virol. 89, 2866–2874 (2015).
Wiens, M. E. & Smith, J. G. alpha-Defensin HD5 inhibits human papillomavirus 16 infection via capsid stabilization and redirection to the lysosome. mBio 8, e02304-16 (2017).
Raveschot, C. et al. Production of bioactive peptides by lactobacillus species: from gene to application. Front. Microbiol. 9, 2354 (2018).
Sadat-Mekmene, L., Genay, M., Atlan, D., Lortal, S. & Gagnaire, V. Original features of cell-envelope proteinases of Lactobacillus helveticus: a review. Int. J. Food Microbiol. 146, 1–13 (2011).
Rollison, D. E., Viarisio, D., Amorrortu, R. P., Gheit, T. & Tommasino, M. An emerging issue in oncogenic virology: the role of beta human papillomavirus types in the development of cutaneous squamous cell carcinoma. J. Virol. 93, e01003–18 (2019).
Tummers, B. et al. The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFkappaB activation. Nat. Commun. 6, 6537 (2015).
Schrofelbauer, B., Polley, S., Behar, M., Ghosh, G. & Hoffmann, A. NEMO ensures signaling specificity of the pleiotropic IKKbeta by directing its kinase activity toward IkappaBalpha. Mol. Cell 47, 111–121 (2012).
Griffiths, D. A. et al. Merkel cell polyomavirus small T antigen targets the NEMO adaptor protein to disrupt inflammatory signaling. J. Virol. 87, 13853–13867 (2013).
Cicchini, L. et al. High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes. Sci. Rep. 7, 3633 (2017).
Lee, J. O. et al. Hepatitis B virus X protein represses E-cadherin expression via activation of DNA methyltransferase 1. Oncogene 24, 6617–6625 (2005).
Kanarek, N. & Ben-Neriah, Y. Regulation of NF-kappaB by ubiquitination and degradation of the IkappaBs. Immunological Rev. 246, 77–94 (2012).
Liu, C. et al. beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. Proc. Natl Acad. Sci. USA 96, 6273–6278 (1999).
Busino, L. et al. Degradation of Cdc25A by beta-TrCP during S phase and in response to DNA damage. Nature 426, 87–91 (2003).
Ison, C. A. & Hay, P. E. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sexually transmitted Infect. 78, 413–415 (2002).
Chawla, R., Bhalla, P., Chadha, S., Grover, S. & Garg, S. Comparison of Hay’s criteria with Nugent’s scoring system for diagnosis of bacterial vaginosis. BioMed. Res. Int. 2013, 365194 (2013).
Bhujel, R., Mishra, S. K., Yadav, S. K., Bista, K. D. & Parajuli, K. Comparative study of Amsel’s criteria and Nugent scoring for diagnosis of bacterial vaginosis in a tertiary care hospital, Nepal. BMC Infect. Dis. 21, 825 (2021).
Sha, B. E. et al. Utility of Amsel criteria, Nugent score, and quantitative PCR for Gardnerella vaginalis, Mycoplasma hominis, and Lactobacillus spp. for diagnosis of bacterial vaginosis in human immunodeficiency virus-infected women. J. Clin. Microbiol. 43, 4607–4612 (2005).
Arbeit, J. M., Howley, P. M. & Hanahan, D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc. Natl Acad. Sci. USA 93, 2930–2935 (1996).
Elson, D. A. et al. Sensitivity of the cervical transformation zone to estrogen-induced squamous carcinogenesis. Cancer Res. 60, 1267–1275 (2000).
Gerard, C. et al. Accurate Control of 17beta-estradiol long-term release increases reliability and reproducibility of preclinical animal studies. J. mammary gland Biol. neoplasia 22, 1–11 (2017).
Goldman, J. M., Murr, A. S. & Cooper, R. L. The rodent estrous cycle: characterization of vaginal cytology and its utility in toxicological studies. Birth defects Res. Part B, Dev. Reprod. Toxicol. 80, 84–97 (2007).
Wimmer-Scherr, C., et al. Comparison of fecal microbiota of horses suffering from atypical myopathy and healthy co-grazers. Animals (Basel) 11, 506 (2021).
Cerri, S. et al. Effect of oral administration of omeprazole on the microbiota of the gastric glandular mucosa and feces of healthy horses. J. Vet. Intern Med. 34, 2727–2737 (2020).
Fettweis, G. et al. RIP3 antagonizes a TSC2-mediated pro-survival pathway in glioblastoma cell death. Biochimica et. Biophysica Acta Mol. Cell Res. 1864, 113–124 (2017).
Blomme, A. et al. Myoferlin regulates cellular lipid metabolism and promotes metastases in triple-negative breast cancer. Oncogene 36, 2116–2130 (2017).
Lambert, P. F. et al. Using an immortalized cell line to study the HPV life cycle in organotypic “raft” cultures. Methods Mol. Med. 119, 141–155 (2005).
Meuris, F. et al. The CXCL12/CXCR4 signaling pathway: a new susceptibility factor in human papillomavirus pathogenesis. PLoS Pathog. 12, e1006039 (2016).
Nys, G., Cobraiville, G. & Fillet, M. Multidimensional performance assessment of micro pillar array column chromatography combined to ion mobility-mass spectrometry for proteome research. Analytica Chim. Acta 1086, 1–13 (2019).
Herfs, M. et al. A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalised medicine. Br. J. Cancer 118, 1302–1312 (2018).
Herfs, M. et al. A novel blueprint for ‘top down’ differentiation defines the cervical squamocolumnar junction during development, reproductive life, and neoplasia. J. Pathol. 229, 460–468 (2013).
Herfs, M. et al. Transforming growth factor-beta1-mediated Slug and Snail transcription factor up-regulation reduces the density of Langerhans cells in epithelial metaplasia by affecting E-cadherin expression. Am. J. Pathol. 172, 1391–1402 (2008).
Wang, X., Spandidos, A., Wang, H. & Seed, B. PrimerBank: a PCR primer database for quantitative gene expression analysis, 2012 update. Nucleic Acids Res. 40, D1144–D1149 (2012).
Poirson, J. et al. Mapping the interactome of HPV E6 and E7 oncoproteins with the ubiquitin-proteasome system. FEBS J. 284, 3171–3201 (2017).
Cassonnet, P. et al. Benchmarking a luciferase complementation assay for detecting protein complexes. Nat. Methods 8, 990–992 (2011).
Nokin, M. J., et al. Methylglyoxal, a glycolysis side-product, induces Hsp90 glycation and YAP-mediated tumor growth and metastasis. eLife 5, e19375 (2016).
